Brown Brothers Harriman & Co. Decreases Stake in Danaher Co. (NYSE:DHR)

Brown Brothers Harriman & Co. lessened its position in shares of Danaher Co. (NYSE:DHR) by 0.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,000 shares of the conglomerate’s stock after selling 63 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Danaher were worth $4,170,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in Danaher in the second quarter worth $25,000. CarsonAllaria Wealth Management Ltd. bought a new position in shares of Danaher in the 2nd quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new stake in Danaher during the third quarter worth approximately $40,000. Darwin Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter worth approximately $55,000. Finally, MFA Wealth Advisors LLC purchased a new position in Danaher during the 2nd quarter valued at $51,000. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Performance

DHR stock opened at $237.65 on Tuesday. Danaher Co. has a one year low of $215.68 and a one year high of $281.70. The firm has a market cap of $171.65 billion, a price-to-earnings ratio of 45.35, a PEG ratio of 4.34 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm has a 50-day simple moving average of $257.38 and a two-hundred day simple moving average of $259.93.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same period in the previous year, the company earned $2.02 earnings per share. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Wall Street Analyst Weigh In

A number of analysts have weighed in on DHR shares. Stifel Nicolaus increased their target price on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research note on Tuesday, October 1st. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Finally, StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a report on Monday, November 18th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.